Myelofibrosis - 44 Studies Found Active, not recruiting : Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence : Primary Myelofibrosis : 2010-07-15 : Drug: Pomalidomide 0.5 mg Poma Recruiting : Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis : Primary Myelofibrosis Secondary Myelofibr : 2016-09-26 : Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Completed : A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis : Primary Myelofibrosis (MF) : 2014-03-12 : Drug: Ruxolitinib Recruiting : JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis : Primary Myelofibrosis Secondary Myelofibr : 2014-09-12 : Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Completed : A Phase 2 Study With IPI-926 in Patients With Myelofibrosis : Primary Myelofibrosis Fibrosis, Bone Marrow : 2011-06-09 : Drug: IPI-926 Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive dise Completed : Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis : Myelodysplastic Syndrome Primary Myelofibrosis : 2011-01-18 Recruiting : Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis : Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase : 2016-08-09 : Biological: Durvalumab Given I
